RedHill Biopharma Reports Opaganib Plus Venetoclax Halves CLL Cell Counts in Preclinical Study

Reuters12-15

RedHill Biopharma Reports Opaganib Plus Venetoclax Halves CLL Cell Counts in Preclinical Study

RedHill Biopharma Ltd. announced positive in vivo results from a study evaluating the combination of opaganib and venetoclax in the treatment of Chronic Lymphocytic Leukemia (CLL). The data indicate that adding opaganib, a sphingosine kinase 2 (SPHK2) inhibitor, to venetoclax reduced CLL cell counts by 50% compared to controls in a mouse model. The study also reported lowered counts of CD3+, CD4+, and CD8+ T cells, as well as reduced PD1 expression in CD8+ cells. These findings suggest a potential role for opaganib as an add-on therapy in venetoclax-resistant CLL. The results have already been announced by the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO47346) on December 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591645626?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591645626","market":"nz","top_or_hot":-1,"title":"RedHill Biopharma Reports Opaganib Plus Venetoclax Halves CLL Cell Counts in Preclinical Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      RedHill Biopharma Reports Opaganib Plus Venetoclax Halves CLL Cell Counts in Preclinical Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        RedHill Biopharma Ltd. announced positive in vivo results from a study evaluating the combination of opaganib and venetoclax in the treatment of Chronic Lymphocytic Leukemia (CLL). The data indicate that adding opaganib, a sphingosine kinase 2 (SPHK2) inhibitor, to venetoclax reduced CLL cell counts by 50% compared to controls in a mouse model. The study also reported lowered counts of CD3+, CD4+, and CD8+ T cells, as well as reduced PD1 expression in CD8+ cells. These findings suggest a potential role for opaganib as an add-on therapy in venetoclax-resistant CLL. The results have already been announced by the company.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/RDHL\">Redhill Biopharma Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO47346) on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RedHill Biopharma Reports Opaganib Plus Venetoclax Halves CLL Cell Counts in Preclinical Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRedHill Biopharma Reports Opaganib Plus Venetoclax Halves CLL Cell Counts in Preclinical Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-15 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      RedHill Biopharma Reports Opaganib Plus Venetoclax Halves CLL Cell Counts in Preclinical Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        RedHill Biopharma Ltd. announced positive in vivo results from a study evaluating the combination of opaganib and venetoclax in the treatment of Chronic Lymphocytic Leukemia (CLL). The data indicate that adding opaganib, a sphingosine kinase 2 (SPHK2) inhibitor, to venetoclax reduced CLL cell counts by 50% compared to controls in a mouse model. The study also reported lowered counts of CD3+, CD4+, and CD8+ T cells, as well as reduced PD1 expression in CD8+ cells. These findings suggest a potential role for opaganib as an add-on therapy in venetoclax-resistant CLL. The results have already been announced by the company.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/RDHL\">Redhill Biopharma Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO47346) on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLbs16Gj:1","article_id":"2591645626","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591645626","pubTimestamp":1765800093,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"RedHill Biopharma Ltd. announced positive in vivo results from a study evaluating the combination of opaganib and venetoclax in the treatment of Chronic Lymphocytic Leukemia . The data indicate that adding opaganib, a sphingosine kinase 2  inhibitor, to venetoclax reduced CLL cell counts by 50% compared to controls in a mouse model. The study also reported lowered counts of CD3+, CD4+, and CD8+ T cells, as well as reduced PD1 expression in CD8+ cells. These findings suggest a potential role for opaganib as an add-on therapy in venetoclax-resistant CLL. The results have already been announced by the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news br","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RDHL":"Redhill Biopharma Ltd"},"translate_title":"RedHill Biopharma报告Opaganib加Venetoclax在临床前研究中将CLL细胞计数减半","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDHL":0.9},"content_text":"RedHill Biopharma Reports Opaganib Plus Venetoclax Halves CLL Cell Counts in Preclinical Study\n    \n\n        RedHill Biopharma Ltd. announced positive in vivo results from a study evaluating the combination of opaganib and venetoclax in the treatment of Chronic Lymphocytic Leukemia (CLL). The data indicate that adding opaganib, a sphingosine kinase 2 (SPHK2) inhibitor, to venetoclax reduced CLL cell counts by 50% compared to controls in a mouse model. The study also reported lowered counts of CD3+, CD4+, and CD8+ T cells, as well as reduced PD1 expression in CD8+ cells. These findings suggest a potential role for opaganib as an add-on therapy in venetoclax-resistant CLL. The results have already been announced by the company.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO47346) on December 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591645626","isCrawlerRequest":true}